SB 269970

SB-269970 is a drug and research chemical developed by GlaxoSmithKline used in scientific studies. It is believed to act as a selective 5-HT₇ receptor antagonist (EC₅₀ = 1.25 nM) (or possibly inverse agonist). A subsequent study in guinea pig at 10 uM showed that it also blocks the α₂-adrenergic receptor activity. The significant difference in test concentrations, however, confirms the selectivity of SB-269970 for the 5-HT₇ receptor.

SB-269970 is used to study the 5-HT₇ receptors which are thought to be involved in the function of several areas of the brain such as the hippocampus and thalamus, and regulation of dopamine release in the ventral tegmental area. Possible therapeutic uses for SB-269970 and other 5-HT₇ antagonists include the treatment of anxiety and depression, and nootropic effects have also been noted in animal studies.